Biologics Market to Expand at a CAGR of 9.25% Over 2022-2027

0
Biologics Market
Biologics Market

According to IMARC Group latest report titled “Biologics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”, offers a comprehensive analysis of the industry, which comprises insights on Biologics market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the global market. The global biologics market reached a value of US$ 294 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 501.9 Billion by 2027, exhibiting a CAGR of 9.25% during 2022-2027.

Biologics refers to the disease-modifying antirheumatic drugs (DMARDs) that contain components of living organisms. It includes several products that are derived from microorganisms, humans, and animals using biotechnological solutions, such as vaccines, blood, cells, genes, tissues, allergens, etc. Biologics consists of proteins that control the action of cellular processes, modify human hormones, and activate constituents of the immune system. It also aids in reducing the swelling of joints, improving the quality of the skin, minimizing gastrointestinal inflammation, etc. As a result, biologics is widely utilized to treat various medical ailments, including ulcerative colitis, arthritis, autoimmune disorders, Crohn’s disease, etc.

As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

Market Trends:

The increasing incidences of numerous chronic diseases, such as cancer, psoriasis, diabetes, etc., are primarily driving the biologics market across the globe. Furthermore, the growing consumer awareness towards the benefits of gene-based biologics in the treatment of several diseases and disorders, such as migraine and muscular degeneration, is also propelling the market growth. In line with this, the launch of various favorable initiatives by government bodies to promote the availability of biologics-related solutions is acting as another significant growth-inducing factor. Additionally, the introduction of novel biologic therapeutics for cancer treatments is further augmenting the global market. Apart from this, the development of advanced oral variants for the treatment of rheumatoid arthritis is projected to fuel the biologics market over the forecasted period.

View Full Report with TOC & List of Figure: https://www.imarcgroup.com/biologics-market

Competitive Landscape with Key players:

The report has also analysed the competitive landscape of the market with some of the key players being.

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi

Biologics Market Segmentation:

Our report has categorized the market based on region, source, product, disease and manufacturing.

Breakup by Source:

  • Microbial
  • Mammalian
  • Others

Breakup by Product:

  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Proteins
  • Antisense, RNAi and Molecular Therapy
  • Others

Breakup by Disease:

  • Oncology
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others

Breakup by Manufacturing:

  • Outsourced
  • In-House

Breakup by Region:

  • North America (United States, Canada)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Others)
  • Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

Key highlights of the report:

  • Market Performance (2016-2021)
  • Market Outlook (2022-2027)
  • Porter’s Five Forces Analysis
  • Market Drivers and Success Factors
  • SWOT Analysis
  • Value Chain
  • Comprehensive Mapping of the Competitive Landscape

Table of Contents:

1   Preface
2   Scope and Methodology

2.1    Objectives of the Study
2.2    Stakeholders
2.3    Data Sources
2.3.1    Primary Sources
2.3.2    Secondary Sources
2.4    Market Estimation
2.4.1    Bottom-Up Approach
2.4.2    Top-Down Approach
2.5    Forecasting Methodology
3   Executive Summary
4   Introduction

4.1    Overview
4.2    Key Industry Trends
5   Global Biologics Market
5.1    Market Overview
5.2    Market Performance
5.3    Impact of COVID-19
5.4    Market Forecast
6   Market Breakup by Source
6.1    Microbial
6.1.1 Market Trends
6.1.2 Market Forecast
6.2    Mammalian
6.2.1 Market Trends
6.2.2 Market Forecast
6.3    Others
6.3.1 Market Trends
6.3.2 Market Forecast
7   Market Breakup by Product
7.1    Monoclonal Antibodies
7.1.1 Market Trends
7.1.2 Market Forecast
7.2    Vaccines
7.2.1 Market Trends
7.2.2 Market Forecast
7.3    Recombinant Proteins
7.3.1 Market Trends
7.3.2 Market Forecast
7.4    Antisense, RNAi and Molecular Therapy
7.4.1 Market Trends
7.4.2 Market Forecast
7.5    Others
7.5.1 Market Trends
7.5.2 Market Forecast
8   Market Breakup by Disease
8.1    Oncology
8.1.1 Market Trends
8.1.2 Market Forecast
8.2    Immunological Disorders
8.2.1 Market Trends
8.2.2 Market Forecast
8.3    Cardiovascular Disorders
8.3.1 Market Trends
8.3.2 Market Forecast
8.4    Hematological Disorders
8.4.1 Market Trends
8.4.2 Market Forecast
8.5    Others
8.5.1 Market Trends
8.5.2 Market Forecast
9   Market Breakup by Manufacturing
9.1    Outsourced
9.1.1 Market Trends
9.1.2 Market Forecast
9.2    In-House
9.2.1 Market Trends
9.2.2 Market Forecast
10  Market Breakup by Region
10.1    North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
10.2    Asia-Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
10.3    Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
10.4    Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
10.5    Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast
11  SWOT Analysis
11.1    Overview
11.2    Strengths
11.3    Weaknesses
11.4    Opportunities
11.5    Threats
12  Value Chain Analysis
13  Porters Five Forces Analysis

13.1    Overview
13.2    Bargaining Power of Buyers
13.3    Bargaining Power of Suppliers
13.4    Degree of Competition
13.5    Threat of New Entrants
13.6    Threat of Substitutes
14  Price Analysis
15  Competitive Landscape

15.1    Market Structure
15.2    Key Players
15.3    Profiles of Key Players
15.3.1    AbbVie Inc.
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2    Amgen Inc.
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.2.4 SWOT Analysis
15.3.3    AstraZeneca plc
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4    F. Hoffmann-La Roche Ltd
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 SWOT Analysis
15.3.5    GlaxoSmithKline plc
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 Financials
15.3.5.4 SWOT Analysis
15.3.6    Johnson & Johnson
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.6.4 SWOT Analysis
15.3.7    Merck KGaA
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8    Novartis AG
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9    Pfizer Inc.
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10    Sanofi
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis

We are updating our reports, If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Competitive landscape, etc. Click request free sample report, the report will be delivered to you in PDF format via email within 24 to 48 hours after the payment confirmation.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US:
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

LEAVE A REPLY

Please enter your comment!
Please enter your name here